Result of Placing & Notice of General Meeting

RNS Number : 3986D

Angle PLC

27 October 2020

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL ("RESTRICTED JURISDICTION"). THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. THE SECURITIES DISCUSSED HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT. NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR THE REPUBLIC OF IRELAND.

FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN ANGLE PLC IN ANY JURISDICTION IN WHICH ANY SUCH, OFFER OR SOLICITATION WOULD BE UNLAWFUL.

27 October 2020

ANGLE plc

("ANGLE" or the "Company")

Result of Placing and Notice of General Meeting

 Funds will accelerate commercialisation of Parsortix system that is currently under FDA substantive review 

ANGLE believes that the earliest prospect of FDA clearance is Q2 CY21*

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that, further to the announcement made earlier today, the Company has successfully raised gross proceeds of £19.6 million by conditionally placing 42,608,695 Placing Shares at a price of 46 pence per New Ordinary Share (the "Issue Price") with new and existing investors. 

The Issue Price represents a discount of approximately 5.15 per cent. to the closing mid-market price of an Ordinary Share of 48.5 pence on 26 October 2020.

A circular to Shareholders is expected to be posted shortly, including details of the General Meeting and the Resolutions and will be available on the Company's website, www.angleplc.com .

The General Meeting will be held at 10.00 a.m. on 13 November 2020 at the offices of the Company at 10 Nugent Road, The Surrey Research Park, Guildford, Surrey GU2 7AF.

* ANGLE is following a De Novo FDA process for Parsortix, as there is no predicate device. Consequently, there is inherent uncertainty over the timing of the process and its ultimate success.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We are grateful for the strong support of existing and new shareholders. As well as strengthening the Company's balance sheet, the proceeds from the Placing will allow us to progress commercialisation of our Parsortix system, whilst it is under substantive review with FDA. ANGLE believes that the earliest prospect of FDA clearance for Parsortix, as a platform that harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer, is Q2 CY21.*"

Use of Proceeds:

Ongoing operations	£6.6m
-  Metastatic breast cancer FDA clearance
-  Ovarian cancer LDT**
-  Balance sheet / working capital as well as expenses in connection with the Placing
Establishing clinical laboratories for pharma services and LDTs**	£5.0m
Parsortix assay development and clinical studies	£6.0m
Commercial expansion including reimbursement**, sales and partnerships	£2.0m
Total	£19.6m

**The term "LDT" refers to a laboratory developed test and "reimbursement" refers to codes for the payment for clinical services.

General Meeting and Admission

The Placing is conditional, inter alia, upon the passing of the Resolutions at the General Meeting and upon Admission becoming effective.

Upon Admission the Enlarged Issued Share Capital is expected to be 215,405,178 Ordinary Shares. On this basis, the Placing Shares will represent approximately 19.78 per cent. of the Company's Enlarged Issued Share Capital.

Application will be made for the 42,608,695 Placing Shares to be admitted to trading on AIM.

Subject to the Resolutions having been passed and the Placing Agreement not having been terminated in accordance with its terms, it is anticipated that admission of the Placing Shares will occur at 8.00 a.m. on or around 16 November 2020.

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released earlier today unless the context requires otherwise.

For further information:

ANGLE plc	[phone]
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley ECM - Alice Lane, Sunila de Silva	[phone]
WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee	[phone]
Beech Hill Securities (US Broker) George Billington	[phone]
FTI Consulting Simon Conway, Ciara Martin, Stephanie Cuthbert Matthew Ventimiglia (US)	[phone]

This Announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Prior to publication, certain information contained within this Announcement was deemed to constitute inside information for the purposes of Article 7 of MAR. In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. Due to the publication of this Announcement, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.

 

END

 

 

ROIFLFFTIRLDFII